ArticleJournal of neurology2022

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.

Clara G Chisari et al.PubMed ↗Publisher ↗

No numbers read from the abstract.